

# Impact of Meningococcal Serogroup C Conjugate Vaccin

Journal of Infectious Diseases

197, 737-743

DOI: 10.1086/527401

Citation Report

#	ARTICLE	IF	CITATIONS
1	Genetics and evolution of <i>Neisseria meningitidis</i> : Importance for the epidemiology of meningococcal disease. <i>Infection, Genetics and Evolution</i> , 2008, 8, 558-565.	1.0	96
2	Herd immunity: recent uses in vaccine assessment. <i>Expert Review of Vaccines</i> , 2008, 7, 1493-1506.	2.0	32
3	Population genomics: diversity and virulence in the <i>Neisseria</i> . <i>Current Opinion in Microbiology</i> , 2008, 11, 467-471.	2.3	84
4	Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era. <i>Vaccine Journal</i> , 2008, 15, 1694-1698.	3.2	66
5	Opa Protein Repertoires of Disease-Causing and Carried Meningococci. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3033-3041.	1.8	15
6	Vaccines for the Unvaccinated: Protecting the Herd. <i>Journal of Infectious Diseases</i> , 2008, 197, 643-645.	1.9	21
7	Meningococcal tetravalent conjugate vaccine. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1941-1946.	1.4	10
8	Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. <i>Expert Review of Vaccines</i> , 2009, 8, 851-861.	2.0	185
9	Structural and Kinetic Characterizations of the Polysialic Acid O-Acetyltransferase OatWY from <i>Neisseria meningitidis</i> . <i>Journal of Biological Chemistry</i> , 2009, 284, 24501-24511.	1.6	18
10	Absence of <i>Neisseria meningitidis</i> Serogroup C-Specific Antibodies during the First Year of Life in The Netherlands: an Age Group at Risk?. <i>Vaccine Journal</i> , 2009, 16, 1521-1523.	3.2	2
11	Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents. <i>Clinical Infectious Diseases</i> , 2009, 49, e1-e10.	2.9	96
12	Binding of Complement Factor H (fH) to <i>Neisseria meningitidis</i> Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera. <i>Infection and Immunity</i> , 2009, 77, 764-769.	1.0	155
14	Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. <i>Nature Reviews Immunology</i> , 2009, 9, 213-220.	10.6	389
15	Sampling methods to detect carriage of <i>Neisseria meningitidis</i> ; literature review. <i>Journal of Infection</i> , 2009, 58, 103-107.	1.7	36
16	Meningococcal carriage and disease—Population biology and evolution. <i>Vaccine</i> , 2009, 27, B64-B70.	1.7	302
17	Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. <i>Vaccine</i> , 2009, 27, B117-B125.	1.7	69
18	Meningococcal C conjugate vaccine: The experience in England and Wales. <i>Vaccine</i> , 2009, 27, B20-B29.	1.7	144
19	Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. <i>Vaccine</i> , 2009, 27, 4408-4411.	1.7	23

#	ARTICLE	IF	CITATIONS
20	Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. <i>Vaccine</i> , 2009, 27, 5574-5580.	1.7	80
21	Meningococcal vaccines: a neglected topic in travel medicine?. <i>Expert Review of Vaccines</i> , 2009, 8, 1343-1350.	2.0	16
22	Clinical and laboratory evidence for <i>Neisseria meningitidis</i> biofilms. <i>Future Microbiology</i> , 2009, 4, 555-563.	1.0	15
24	<i>Neisseria meningitidis</i> : epidemiology, treatment and prevention in adolescents. <i>Current Opinion in Pediatrics</i> , 2009, 21, 437-443.	1.0	47
25	A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 86-91.	1.1	72
26	Biosynthesis and production of polysialic acids in bacteria. <i>Applied Microbiology and Biotechnology</i> , 2010, 86, 1621-1635.	1.7	38
27	Biofilm formation by the human pathogen <i>Neisseria meningitidis</i> . <i>Medical Microbiology and Immunology</i> , 2010, 199, 173-183.	2.6	26
28	Infections Ã mÃ©ningocoque W135Ã©chez lâ€™enfant avec localisations extramÃ©ningÃ©esÃ©: Ã propos de deux cas. <i>Journal De Pediatrie Et De Puericulture</i> , 2010, 23, 275-278.	0.0	0
29	Challenges in immunisation against bacterial infection in children. <i>Early Human Development</i> , 2010, 86, 695-701.	0.8	10
30	Serogroup C <i>Neisseria meningitidis</i> invasive infection: analysis of the possible vaccination strategies for a mass campaign. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2010, 99, 1609-1614.	0.7	9
31	Travelers' Protection Against Meningococcal Disease: A New Vaccine Option. <i>Journal of Travel Medicine</i> , 2010, 17, 18-25.	1.4	4
32	A dual role of extracellular DNA during biofilm formation of <i>Neisseria meningitidis</i> . <i>Molecular Microbiology</i> , 2010, 75, 1355-1371.	1.2	127
34	The Influence of IS1301 in the Capsule Biosynthesis Locus on Meningococcal Carriage and Disease. <i>PLoS ONE</i> , 2010, 5, e9413.	1.1	13
35	Clonal Distribution of Disease-Associated and Healthy Carrier Isolates of <i>Neisseria meningitidis</i> between 1983 and 2005 in Cuba. <i>Journal of Clinical Microbiology</i> , 2010, 48, 802-810.	1.8	21
36	Epidemiological Profile of Meningococcal Disease in the United States. <i>Clinical Infectious Diseases</i> , 2010, 50, S37-S44.	2.9	111
37	Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity. <i>Vaccine Journal</i> , 2010, 17, 840-847.	3.2	193
38	Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy. <i>Clinical Microbiology Reviews</i> , 2010, 23, 740-780.	5.7	334
39	Functional T-Cell Deficiency in Adolescents Who Experience Serogroup C Meningococcal Disease despite Receiving the Meningococcal Serogroup C Conjugate Vaccine. <i>Vaccine Journal</i> , 2010, 17, 1104-1110.	3.2	10

#	ARTICLE	IF	CITATIONS
40	Review of Meningococcal Group B Vaccines. <i>Clinical Infectious Diseases</i> , 2010, 50, S54-S65.	2.9	168
41	Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary School Children in 1999-2000 and Response to a Booster: A Phase 4 Clinical Trial. <i>Clinical Infectious Diseases</i> , 2010, 50, 1601-1610.	2.9	83
42	Young-adult carriers of <i>Neisseria meningitidis</i> in Puglia (Italy): Will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugate vaccines?. <i>Hum Vaccin</i> , 2010, 6, 1025-1027.	2.4	12
43	Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults. <i>Future Microbiology</i> , 2010, 5, 1629-1640.	1.0	6
44	The epidemiology of meningococcal disease and the impact of vaccines. <i>Expert Review of Vaccines</i> , 2010, 9, 285-298.	2.0	116
45	Invasive meningococcal disease and travel. <i>Journal of Infection and Public Health</i> , 2010, 3, 143-151.	1.9	45
46	2010 FIFA World Cup South Africa: Travel health issues and new options for protection against meningococcal disease. <i>Travel Medicine and Infectious Disease</i> , 2010, 8, 68-73.	1.5	12
47	Advances in the Development of Vaccines against <i>Neisseria meningitidis</i> . <i>New England Journal of Medicine</i> , 2010, 362, 1511-1520.	13.9	209
48	Optimizing Protection Against Meningococcal Disease. <i>Clinical Pediatrics</i> , 2010, 49, 586-597.	0.4	9
49	Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis. <i>Clinical Microbiology Reviews</i> , 2010, 23, 467-492.	5.7	652
50	Molecular epidemiology of meningococci: Application of DNA sequence typing. <i>International Journal of Medical Microbiology</i> , 2010, 300, 415-420.	1.5	8
51	Unlocking pathogen genotyping information for public health by mathematical modeling. <i>Trends in Microbiology</i> , 2010, 18, 406-412.	3.5	15
52	Overview of the development and current use of CRM197 conjugate vaccines for pediatric use. <i>Vaccine</i> , 2010, 28, 4335-4339.	1.7	86
53	Meningococcal carriage by age: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 853-861.	4.6	514
55	Hospital Costs, Length of Stay and Mortality Associated with Childhood, Adolescent and Young Adult Meningococcal Disease in the US. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 197-207.	1.0	16
56	Menveo <sup>®</sup> : a novel quadrivalent meningococcal CRM <sub>197</sub> conjugate vaccine against serogroups A, C, W-135 and Y. <i>Expert Review of Vaccines</i> , 2011, 10, 21-33.	2.0	53
57	An update on vaccination against group B streptococcus. <i>Expert Review of Vaccines</i> , 2011, 10, 685-694.	2.0	70
58	<i>Neisseria meningitidis</i> B vaccines. <i>Expert Review of Vaccines</i> , 2011, 10, 1337-1351.	2.0	42

#	ARTICLE	IF	CITATIONS
59	European efforts to harmonize typing of meningococci. <i>International Journal of Medical Microbiology</i> , 2011, 301, 659-662.	1.5	4
60	The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease. <i>Vaccine</i> , 2011, 29, 3363-3371.	1.7	105
61	Mechanisms of meningococcal colonisation. <i>Trends in Microbiology</i> , 2011, 19, 456-463.	3.5	39
62	Pandemic (H1N1) 2009 in Neonates, Japan. <i>Emerging Infectious Diseases</i> , 2011, 17, 1763-1765.	2.0	12
63	From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease. <i>Paediatrics and Child Health</i> , 2011, 16, e61-e64.	0.3	10
64	Carriage of Meningococci by University Students, United Kingdom. <i>Emerging Infectious Diseases</i> , 2011, 17, 1762-1763.	2.0	47
65	Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive disease. <i>Infection and Drug Resistance</i> , 2011, 4, 137.	1.1	22
66	Meningococcal conjugate vaccines: optimizing global impact. <i>Infection and Drug Resistance</i> , 2011, 4, 161.	1.1	13
67	Vaccines for Gonorrhoea: Can We Rise to the Challenge?. <i>Frontiers in Microbiology</i> , 2011, 2, 124.	1.5	83
68	Emergence of Epidemic <i>Neisseria meningitidis</i> Serogroup X Meningitis in Togo and Burkina Faso. <i>PLoS ONE</i> , 2011, 6, e19513.	1.1	108
69	Age-Related Immunity to Meningococcal Serogroup C Vaccination: An Increase in the Persistence of IgG2 Correlates with a Decrease in the Avidity of IgG. <i>PLoS ONE</i> , 2011, 6, e23497.	1.1	11
70	What is the best way to use conjugate vaccines?. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 219-224.	1.3	13
71	Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C <i>Neisseria meningitidis</i> Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, e203-e208.	1.1	13
72	Persistence of Immunity Following a Booster Dose of <i>Haemophilus influenzae</i> Type B-Meningococcal Serogroup C Glycoconjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 197-202.	1.1	28
73	Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 451-455.	1.1	55
74	Vaccine development against <i>Neisseria meningitidis</i> . <i>Microbial Biotechnology</i> , 2011, 4, 20-31.	2.0	15
75	Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines and other potential clinical applications. <i>Biologicals</i> , 2011, 39, 195-204.	0.5	104
76	Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies. <i>Expert Review of Vaccines</i> , 2011, 10, 1717-1730.	2.0	31

#	ARTICLE	IF	CITATIONS
77	Meningococcal disease: The advances and challenges of meningococcal disease prevention. <i>Hum Vaccin</i> , 2011, 7, 828-837.	2.4	20
78	Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 969-985.	1.4	94
79	Changes in Serogroup and Genotype Prevalence Among Carried Meningococci in the United Kingdom During Vaccine Implementation. <i>Journal of Infectious Diseases</i> , 2011, 204, 1046-1053.	1.9	44
80	Nasopharyngeal Colonization by <i>Neisseria lactamica</i> and Induction of Protective Immunity against <i>Neisseria meningitidis</i> . <i>Clinical Infectious Diseases</i> , 2011, 52, 70-77.	2.9	70
81	Potential of Recombinant Opa Proteins as Vaccine Candidates against Hyperinvasive Meningococci. <i>Infection and Immunity</i> , 2011, 79, 2810-2818.	1.0	20
82	Kinetics of Immune Responses to Nasal Challenge With Meningococcal Polysaccharide One Year After Serogroup-C Glycoconjugate Vaccination. <i>Clinical Infectious Diseases</i> , 2011, 52, 1317-1323.	2.9	14
83	Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience. <i>Advances in Preventive Medicine</i> , 2011, 2011, 1-17.	1.1	25
84	Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood. <i>Vaccine Journal</i> , 2011, 18, 2038-2042.	3.2	24
85	Infectious Syndromes in the Pediatric Intensive Care Unit. , 2011, , 1336-1348.		1
86	Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. <i>Hum Vaccin</i> , 2011, 7, 96-101.	2.4	24
87	Characterization of <i>Neisseria meningitidis</i> Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein. <i>Vaccine Journal</i> , 2011, 18, 1002-1014.	3.2	84
88	Meningococcal glycoconjugate vaccines. <i>Hum Vaccin</i> , 2011, 7, 170-182.	2.4	55
89	Serum Antibody Kinetics following Nasal or Parenteral Challenge with Meningococcal Polysaccharide in Healthy Adults. <i>Vaccine Journal</i> , 2011, 18, 424-429.	3.2	7
90	New frontiers in meningococcal vaccines. <i>Expert Review of Vaccines</i> , 2011, 10, 617-634.	2.0	26
91	Challenges for development of meningococcal vaccines in infants and children. <i>Expert Review of Vaccines</i> , 2011, 10, 335-343.	2.0	10
92	Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century. <i>Expert Review of Vaccines</i> , 2011, 10, 1477-1486.	2.0	32
93	Distinct Effects on Diversifying Selection by Two Mechanisms of Immunity against <i>Streptococcus pneumoniae</i> . <i>PLoS Pathogens</i> , 2012, 8, e1002989.	2.1	43
94	Bexsero. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 174-183.	1.4	106

#	ARTICLE	IF	CITATIONS
95	Vaccination and herd immunity. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 243-249.	1.3	98
96	Prevalence of Serum Bactericidal Antibody to Serogroup C <i>Neisseria meningitidis</i> in England a Decade after Vaccine Introduction. <i>Vaccine Journal</i> , 2012, 19, 1126-1130.	3.2	43
97	Seroprevalence of Serum Bactericidal Antibodies against Group W135 and Y Meningococci in England in 2009. <i>Vaccine Journal</i> , 2012, 19, 219-222.	3.2	18
98	Evolutionary and genomic insights into meningococcal biology. <i>Future Microbiology</i> , 2012, 7, 873-885.	1.0	24
99	Lessons learned and applied. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 560-568.	1.4	9
100	A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1882-1891.	1.4	30
101	MenACWY-TT vaccine for active immunization against invasive meningococcal disease. <i>Expert Review of Vaccines</i> , 2012, 11, 523-537.	2.0	23
102	Increase of meningococcal serogroup Y cases in Europe: A reason for concern?. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 685-688.	1.4	22
103	Effect of Increased CRM <sub>197</sub> Carrier Protein Dose on Meningococcal C Bactericidal Antibody Response. <i>Vaccine Journal</i> , 2012, 19, 551-556.	3.2	13
104	B Cell Memory to a Serogroup C Meningococcal Conjugate Vaccine in Childhood and Response to Booster: Little Association with Serum IgG Antibody. <i>Journal of Immunology</i> , 2012, 189, 2673-2681.	0.4	24
105	Resolution of a Meningococcal Disease Outbreak from Whole-Genome Sequence Data with Rapid Web-Based Analysis Methods. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3046-3053.	1.8	72
106	Advances in meningococcal vaccines. <i>Clinical Practice (London, England)</i> , 2012, 9, 101-117.	0.1	4
107	Prevention of serogroup B meningococcal disease. <i>Lancet, The</i> , 2012, 379, 592-594.	6.3	7
108	Abortion: what is the problem?. <i>Lancet, The</i> , 2012, 379, 594-596.	6.3	10
110	Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 757-764.	4.6	137
111	A vaccine to prevent epidemic meningitis in Africa. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 738-739.	4.6	5
112	Nontypeable Pneumococcal Isolates Among Navajo and White Mountain Apache Communities: Are These Really a Cause of Invasive Disease?. <i>Journal of Infectious Diseases</i> , 2012, 206, 73-80.	1.9	25
113	The 2011 Garrod Lecture: From penicillin-binding proteins to molecular epidemiology. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1578-1588.	1.3	13

#	ARTICLE	IF	CITATIONS
114	History of meningococcal vaccines and their serological correlates of protection. <i>Vaccine</i> , 2012, 30, B10-B17.	1.7	49
115	The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines. <i>Vaccine</i> , 2012, 30, B73-B77.	1.7	14
116	Can we, should we, eradicate the meningococcus?. <i>Vaccine</i> , 2012, 30, B52-B56.	1.7	11
117	Meningococcal vaccine development “ from glycoconjugates against MenACWY to proteins against MenB “ potential for broad protection against meningococcal disease. <i>Vaccine</i> , 2012, 30, B18-B25.	1.7	27
118	Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines. <i>Vaccine</i> , 2012, 30, 3710-3716.	1.7	112
119	Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis. <i>Vaccine</i> , 2012, 30, 4023-4027.	1.7	8
121	Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region. <i>Journal of Epidemiology and Global Health</i> , 2012, 2, 23.	1.1	5
122	Quadrivalent meningococcal conjugated vaccine: A routine or selective vaccine in Europe?. <i>Journal of Infection</i> , 2012, 65, 193-196.	1.7	3
123	Meningococcal disease: changes in epidemiology and prevention. <i>Clinical Epidemiology</i> , 2012, 4, 237.	1.5	112
124	Invasive Meningococcal Capsular Group Y Disease, England and Wales, 2007“2009. <i>Emerging Infectious Diseases</i> , 2012, 18, 63-70.	2.0	61
125	<i>Neisseria meningitidis</i> : Biology, Microbiology, and Epidemiology. <i>Methods in Molecular Biology</i> , 2012, 799, 1-20.	0.4	280
126	Novel meningococcal 4<sc>CM</sc>enB vaccine antigens “ prevalence and polymorphisms of the encoding genes in <i>Neisseria gonorrhoeae</i>. <i>Apmis</i> , 2012, 120, 750-760.	0.9	31
127	Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands. <i>BMC Infectious Diseases</i> , 2012, 12, 35.	1.3	39
128	Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. <i>BMC Infectious Diseases</i> , 2013, 13, 116.	1.3	35
129	Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2“10-year-old children: results of an open, randomised, controlled study. <i>European Journal of Pediatrics</i> , 2013, 172, 601-612.	1.3	32
130	The Long Road to an Effective Vaccine for Meningococcus Group B (MenB). <i>Annals of Medicine and Surgery</i> , 2013, 2, 53-56.	0.5	11
131	Effectiveness of meningococcal serogroup C vaccine programmes. <i>Vaccine</i> , 2013, 31, 4477-4486.	1.7	80
132	Controlling serogroup B invasive meningococcal disease: the Canadian perspective. <i>Expert Review of Vaccines</i> , 2013, 12, 505-517.	2.0	15



#	ARTICLE	IF	CITATIONS
133	Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine, 2013, 31, 4416-4420.	1.7	33
134	Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19077-19082.	3.3	52
135	Current developments and trends in childhood immunization. Paediatrics and Child Health (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.2	2
136	From Agadez to Zinder: estimating coverage of the MenAfriVac, conjugate vaccine against meningococcal serogroup A in Niger, September 2010 to January 2012. Vaccine, 2013, 31, 1597-1603.	1.7	20
137	Glycoconjugate vaccines. Expert Opinion on Biological Therapy, 2013, 13, 11-33.	1.4	41
138	Epidemiology of invasive meningococcal disease in Germany, 2002 to 2010, and impact of vaccination with meningococcal C conjugate vaccine. Journal of Infection, 2013, 66, 48-56.	1.7	34
139	Editorial Commentary: The Endgame for Serogroup A Meningococcal Disease in Africa?. Clinical Infectious Diseases, 2013, 56, 364-366.	2.9	6
140	Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa. Mucosal Immunology, 2013, 6, 288-296.	2.7	18
141	A Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C Tetanus Toxoid Conjugate Vaccine Is Immunogenic and Well-tolerated When Coadministered With Diphtheria, Tetanus, Acellular Pertussis Hepatitis B inactivated Poliovirus at 3, 5 and 11 Months of Age. Pediatric Infectious Disease Journal, 2013, 32, 521-529.	1.1	10
142	Meningococcal vaccines. , 2013, , 388-418.		12
143	Meningococcal Polysaccharide A Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years. Vaccine Journal, 2013, 20, 1499-1507.	3.2	16
144	Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Archives of Disease in Childhood, 2013, 98, 686-691.	1.0	23
145	The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2013, 368, 20120147.	1.8	42
146	Acquisition of Meningococcal Serogroup W-135 Carriage in Turkish Hajj Pilgrims Who Had Received the Quadrivalent Meningococcal Polysaccharide Vaccine. Vaccine Journal, 2013, 20, 66-68.	3.2	46
147	Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity. Clinical Infectious Diseases, 2013, 56, 354-363.	2.9	188
148	Cost-effectiveness of vaccination against meningococcal B among Dutch infants. Human Vaccines and Immunotherapeutics, 2013, 9, 1129-1138.	1.4	51
149	Persistence of antibodies in adolescents 18 to 24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 2304-2310.	1.4	69
150	Protein carriers of conjugate vaccines: Characteristics, development and clinical trials. Human Vaccines and Immunotherapeutics, 2013, 9, 2505-2523.	1.4	185

#	ARTICLE	IF	CITATIONS
151	The changing epidemiology of meningococcal disease in North America 1945–2010. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 162-171.	1.4	47
152	Meningococcal disease: diagnosis and prevention. <i>Primary Health Care</i> , 2013, 23, 32-36.	0.0	0
153	The epidemiology of meningococcal disease in Latin America 1945–2010: an unpredictable and changing landscape. <i>Epidemiology and Infection</i> , 2013, 141, 447-458.	1.0	44
154	A Multi-country Evaluation of <i>Neisseria meningitidis</i> Serogroup B Factor H-Binding Proteins and Implications for Vaccine Coverage in Different Age Groups. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1096-1101.	1.1	36
155	Commencement of the Meningococcal Vaccination for the Republic of Korea Army. <i>Infection and Chemotherapy</i> , 2013, 45, 113.	1.0	7
156	Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of <i>Neisseria meningitidis</i> . <i>PLoS ONE</i> , 2014, 9, e107240.	1.1	18
157	Carriage Rate and Effects of Vaccination after Outbreaks of Serogroup C Meningococcal Disease, Brazil, 2010. <i>Emerging Infectious Diseases</i> , 2014, 20, 806-811.	2.0	33
158	Bacterial Meningitis. , 2014, , 361-370.e3.		0
159	Persistent low carriage of serogroup A <i>Neisseria meningitidis</i> two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. <i>BMC Infectious Diseases</i> , 2014, 14, 663.	1.3	52
160	Climate Influences on Meningitis Incidence in Northwest Nigeria. <i>Weather, Climate, and Society</i> , 2014, 6, 62-76.	0.5	14
161	Global practices of meningococcal vaccine use and impact on invasive disease. <i>Pathogens and Global Health</i> , 2014, 108, 11-20.	1.0	59
162	A Consensus Statement. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 284-290.	1.1	15
163	Zapobieganie zakażeniom meningokokowym – jak stosować obecnie dostępne szczepionki. <i>Pediatrica Polska</i> , 2014, 89, 75-81.	0.1	0
164	Loosening the grip of meningococcal disease in Africa. <i>Lancet, The</i> , 2014, 383, 6-8.	6.3	3
165	A vaccine against serogroup B <i>Neisseria meningitidis</i> : dealing with uncertainty. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 426-434.	4.6	50
166	<i>Neisseria meningitidis</i> B vaccines: recent advances and possible immunization policies. <i>Expert Review of Vaccines</i> , 2014, 13, 345-364.	2.0	22
167	Editorial Commentary: Fifteen Years of Protection by Meningococcal C Conjugate Vaccines: Lessons From Disease Surveillance. <i>Clinical Infectious Diseases</i> , 2014, 59, 1222-1224.	2.9	11
168	A Decade of Herd Protection After Introduction of Meningococcal Serogroup C Conjugate Vaccination. <i>Clinical Infectious Diseases</i> , 2014, 59, 1216-1221.	2.9	79

#	ARTICLE	IF	CITATIONS
169	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. <i>Lancet</i> , The, 2014, 384, 2123-2131.	6.3	247
170	Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-DT): A multicenter, open-label, non-randomized, phase III clinical trial. <i>Indian Pediatrics</i> , 2014, 51, 451-456.	0.2	11
171	A model-based analysis: what potential could there be for a <i>S. aureus</i> vaccine in a hospital setting on top of other preventative measures?. <i>BMC Infectious Diseases</i> , 2014, 14, 291.	1.3	8
172	Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 728-734.	0.5	32
173	Molecular and Serological Diversity of <i>Neisseria meningitidis</i> Carrier Strains Isolated from Italian Students Aged 14 to 22 Years. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1901-1910.	1.8	40
174	Childhood immunisation: Recent changes to the routine schedule. <i>Journal of Health Visiting</i> , 2014, 2, 532-540.	0.0	0
175	Vaccines for Prevention of Group B Meningococcal Disease. <i>American Journal of Preventive Medicine</i> , 2015, 49, S345-S354.	1.6	9
176	The Evolution of the Meningitis Vaccine Project. <i>Clinical Infectious Diseases</i> , 2015, 61, S396-S403.	2.9	36
177	Prevalence, Risk Factors and Molecular Characteristics of Meningococcal Carriage Among Brazilian Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1197-1202.	1.1	28
178	Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial. <i>BMC Infectious Diseases</i> , 2015, 15, 409.	1.3	16
179	Oropharyngeal Carriage of <i>Meningococcus</i> in Portugal by Group and Clonal Complex 6 Years After Adolescent Vaccine Campaign. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1267-1269.	1.1	9
180	Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 865-874.	1.1	19
181	Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e298-e307.	1.1	22
182	Recent changes to the routine childhood immunization schedule. <i>Practice Nursing</i> , 2015, 26, 386-392.	0.1	0
183	Clonal Analysis of Meningococci during a 26 Year Period Prior to the Introduction of Meningococcal Serogroup C Vaccines. <i>PLoS ONE</i> , 2015, 10, e115741.	1.1	2
184	Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?. <i>PLoS ONE</i> , 2015, 10, e0138665.	1.1	3
185	Changes in Meningococcal Strains in the Era of a Serogroup C Vaccination Campaign: Trends and Evolution in Belgium during the Period 1997â€”2012. <i>PLoS ONE</i> , 2015, 10, e0139615.	1.1	3
186	Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria. <i>Journal of Immunology Research</i> , 2015, 2015, 1-3.	0.9	3

#	ARTICLE	IF	CITATIONS
187	Neisseria meningitidis. , 2015, , 2425-2445.e6.		8
188	Antibody Persistence in Australian Adolescents Following Meningococcal C Conjugate Vaccination. Pediatric Infectious Disease Journal, 2015, 34, 279-285.	1.1	15
189	Evolving meningococcal immunization strategies. Expert Review of Vaccines, 2015, 14, 505-517.	2.0	26
190	Vaccines for prevention of group B meningococcal disease: Not your father's vaccines. Vaccine, 2015, 33, D32-D38.	1.7	29
191	Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014. Vaccine, 2015, 33, 3678-3681.	1.7	15
192	Meningococcal Carriage Among Georgia and Maryland High School Students. Journal of Infectious Diseases, 2015, 211, 1761-1768.	1.9	29
193	Carbohydrate-Based Vaccines. Methods in Molecular Biology, 2015, 1331, v-vi.	0.4	4
194	Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex. Clinical Infectious Diseases, 2015, 61, 1281-1292.	2.9	50
195	Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. International Journal of Infectious Diseases, 2015, 38, 36-42.	1.5	17
196	Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country. Human Vaccines and Immunotherapeutics, 2015, 11, 875-883.	1.4	13
197	Nasal Inoculation of the Commensal Neisseria lactamica Inhibits Carriage of Neisseria meningitidis by Young Adults: A Controlled Human Infection Study. Clinical Infectious Diseases, 2015, 60, 1512-1520.	2.9	95
198	The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine, 2015, 33, 6529-6536.	1.7	49
199	Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2015, 58, 1314-1343.	7.2	19
200	Bivalent rLP2086 Vaccine (Trumenba®): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years. BioDrugs, 2015, 29, 353-361.	2.2	28
201	Serogroup A meningococcal conjugate vaccines in Africa. Expert Review of Vaccines, 2015, 14, 1441-1458.	2.0	10
202	Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool. Vaccine, 2015, 33, 3933-3939.	1.7	17
203	Glycoconjugate Vaccines: The Regulatory Framework. Methods in Molecular Biology, 2015, 1331, 229-251.	0.4	5
204	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. Journal of Infection, 2015, 71, 43-52.	1.7	61

#	ARTICLE	IF	CITATIONS
205	A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice. <i>Vaccine</i> , 2015, 33, 1317-1323.	1.7	17
206	Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1501-1506.	1.4	2
207	Glycoconjugate vaccines: an update. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 529-546.	1.4	65
208	Resurgence of Vaccine-Preventable Diseases in the United States. <i>Anesthesia and Analgesia</i> , 2016, 122, 1450-1473.	1.1	15
209	Pharyngeal carriage of <i>Neisseria</i> species in the African meningitis belt. <i>Journal of Infection</i> , 2016, 72, 667-677.	1.7	47
210	ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. <i>Clinical Microbiology and Infection</i> , 2016, 22, S37-S62.	2.8	529
211	Meningococcal Vaccinations. <i>Infectious Diseases and Therapy</i> , 2016, 5, 89-112.	1.8	82
212	Fighting <i>Neisseria meningitidis</i> : past and current vaccination strategies. <i>Expert Review of Vaccines</i> , 2016, 15, 1393-1407.	2.0	11
213	Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines. <i>BMC Medicine</i> , 2016, 14, 98.	2.3	10
214	The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines. <i>Journal of Adolescent Health</i> , 2016, 59, S3-S11.	1.2	159
215	Herd Protection v. Vaccine Abstention. <i>American Journal of Law and Medicine</i> , 2016, 42, 621-641.	0.5	2
216	Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation. <i>Vaccine</i> , 2016, 34, 4690-4697.	1.7	63
217	Metabolic Glycoengineering with <i>N</i> -Acyl Side Chain Modified Mannosamines. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 9482-9512.	7.2	105
218	Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination. <i>Vaccine</i> , 2016, 34, 6309-6315.	1.7	15
219	Metabolisches Glykoengineering mit <i>N</i> -Acyl-Seitenketten-modifizierten Mannosaminen. <i>Angewandte Chemie</i> , 2016, 128, 9632-9665.	1.6	29
221	Density Distribution of Pharyngeal Carriage of <i>Meningococcus</i> in Healthy Young Adults. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1080-1085.	1.1	13
222	Variations in <i>Neisseria meningitidis</i> carriage by socioeconomic status: a cross-sectional study. <i>Journal of Public Health</i> , 2016, 38, 61-70.	1.0	13
223	Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. <i>Expert Review of Vaccines</i> , 2016, 15, 641-658.	2.0	59

#	ARTICLE	IF	CITATIONS
224	Global epidemiology of capsular group W meningococcal disease (1970–2015): Multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex. <i>Vaccine</i> , 2016, 34, 1515-1523.	1.7	75
225	Genomic Analysis of Serogroup Y <i>Neisseria meningitidis</i> Isolates Reveals Extensive Similarities Between Carriage-Associated and Disease-Associated Organisms. <i>Journal of Infectious Diseases</i> , 2016, 213, 1777-1785.	1.9	12
226	Carriage of <i>Neisseria meningitidis</i> in the Hajj and Umrah mass gatherings. <i>International Journal of Infectious Diseases</i> , 2016, 47, 65-70.	1.5	32
227	Carriage and transmission of <i>Neisseria meningitidis</i> . , 2016, , 15-23.		5
228	What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience. <i>Paediatric Drugs</i> , 2016, 18, 83-87.	1.3	6
229	Impact of vaccination on meningococcal epidemiology. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1051-1055.	1.4	22
230	Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 451-466.	1.4	6
231	Reduction in <i>Neisseria meningitidis</i> infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994–2012 series. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 467-473.	1.4	11
232	Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. <i>Pathogens and Global Health</i> , 2017, 111, 1-6.	1.0	42
233	High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine. <i>Genome Medicine</i> , 2017, 9, 11.	3.6	15
234	Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 573.e1-573.e7.	2.8	27
235	Recent Progress in the Prevention of Serogroup B Meningococcal Disease. <i>Vaccine Journal</i> , 2017, 24, .	3.2	29
236	From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy. <i>International Journal of Infectious Diseases</i> , 2017, 60, 98-102.	1.5	10
237	Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination. <i>Vaccine</i> , 2017, 35, 2949-2954.	1.7	1
238	Frequent capsule switching in “ultra-virulent” meningococci “Are we ready for a serogroup B ST-11 complex outbreak?”. <i>Journal of Infection</i> , 2017, 75, 95-103.	1.7	30
239	An unwanted guest: <i>Neisseria meningitidis</i> carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 689-701.	2.0	11
240	Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review. <i>Journal of Infection</i> , 2017, 75, 81-94.	1.7	12
241	Bacterial meningitis in Finland, 1995–2014: a population-based observational study. <i>BMJ Open</i> , 2017, 7, e015080.	0.8	42



#	ARTICLE	IF	CITATIONS
242	Novel approaches to <i>Neisseria meningitidis</i> vaccine design. <i>Pathogens and Disease</i> , 2017, 75, .	0.8	32
243	University vaccine campaign increases meningococcal ACWY vaccine coverage. <i>Public Health</i> , 2017, 145, 1-3.	1.4	14
244	Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006â€“2015. <i>Journal of Infection</i> , 2017, 74, 564-574.	1.7	51
245	The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004â€“2014. <i>Vaccine</i> , 2017, 35, 2034-2041.	1.7	156
246	Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. <i>Vaccine</i> , 2017, 35, 2025-2033.	1.7	30
247	Potential impact of the 4CMenB vaccine on oropharyngeal carriage of <i>Neisseria meningitidis</i> . <i>Journal of Infection</i> , 2017, 75, 511-520.	1.7	4
248	New insights about functional and cross-reactive properties of antibodies generated against recombinant TbpBs of <i>Haemophilus parasuis</i> . <i>Scientific Reports</i> , 2017, 7, 10377.	1.6	17
249	Effect of Vaccine-Elicited Antibodies on Colonization of <i>Neisseria meningitidis</i> Serogroup B and C Strains in a Human Bronchial Epithelial Cell Culture Model. <i>Vaccine Journal</i> , 2017, 24, .	3.2	7
250	Where next? The emergence of hypervirulent W meningococcus in the Netherlands. <i>Lancet Public Health</i> , The, 2017, 2, e443-e444.	4.7	2
251	Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination. <i>Vaccine</i> , 2017, 35, 4753-4760.	1.7	18
252	The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. <i>Expert Review of Vaccines</i> , 2017, 16, 313-328.	2.0	194
253	Investigation of correlates of protection against pharyngeal carriage of <i>Neisseria meningitidis</i> genogroups W and Y in the African meningitis belt. <i>PLoS ONE</i> , 2017, 12, e0182575.	1.1	6
254	Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017, 112, 237-246.	0.8	10
255	Rise in Group W Meningococcal Carriage in University Students, United Kingdom. <i>Emerging Infectious Diseases</i> , 2017, 23, 1009-1011.	2.0	33
256	Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI). <i>Journal of Infection</i> , 2018, 76, 429-437.	1.7	44
257	MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged 10 Years. <i>Drugs</i> , 2018, 78, 257-268.	4.9	27
258	Limited Impact of Adolescent Meningococcal ACWY Vaccination on <i>Neisseria meningitidis</i> Serogroup W Carriage in University Students. <i>Journal of Infectious Diseases</i> , 2018, 217, 608-616.	1.9	22
259	Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, e66-e71.	1.1	1

#	ARTICLE	IF	CITATIONS
260	Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1131-1137.	1.4	9
261	<i>Neisseria meningitidis</i> serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1070-1074.	1.4	13
262	Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1118-1130.	1.4	43
263	Progress toward the global control of <i>Neisseria meningitidis</i> : 21st century vaccines, current guidelines, and challenges for future vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1146-1160.	1.4	62
264	Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1107-1115.	1.4	39
265	Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation. <i>PLoS ONE</i> , 2018, 13, e0209919.	1.1	6
266	A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec. <i>MSphere</i> , 2018, 3, .	1.3	8
267	Initial validation of a simulation model for estimating the impact of serogroup A <i>Neisseria meningitidis</i> vaccination in the African meningitis belt. <i>PLoS ONE</i> , 2018, 13, e0206117.	1.1	6
268	Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents. <i>Journal of Adolescent Health</i> , 2018, 63, 269-279.	1.2	8
269	Invasive Meningococcal Disease due to group C <i>N. meningitidis</i> ST11 (cc11): The Tuscany cluster 2015-2016. <i>Vaccine</i> , 2018, 36, 5962-5966.	1.7	8
270	Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing <i>Neisseria meningitidis</i> Isolates, United Kingdom, 2010-2016. <i>Emerging Infectious Diseases</i> , 2018, 24, 673-682.	2.0	24
271	Vaccine-preventable severe morbidity and mortality caused by meningococcus and pneumococcus: A population-based study in France. <i>Paediatric and Perinatal Epidemiology</i> , 2018, 32, 442-447.	0.8	15
272	Are lactoferrin receptors in Gram-negative bacteria viable vaccine targets?. <i>BioMetals</i> , 2018, 31, 381-398.	1.8	5
273	Mass chemoprophylaxis for control of outbreaks of meningococcal disease. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e272-e281.	4.6	23
274	Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines. , 2018, , 619-643.e11.		7
275	Meningococcal Capsular Group B Vaccines. , 2018, , 644-662.e6.		6
276	Formulation Development of Glycoconjugate Vaccines for Low- and Middle-Income Countries. <i>ACS Symposium Series</i> , 2018, , 197-228.	0.5	1
277	B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of <i>Neisseria meningitidis</i> in adolescents. <i>BMJ Open</i> , 2018, 8, e020988.	0.8	28



#	ARTICLE	IF	CITATIONS
278	A Safety and Immunogenicity Study of a Single Dose of a Meningococcal (Groups A, C, W, and Y) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MEN-ACWY-D) in Healthy Japanese Participants. <i>Japanese Journal of Infectious Diseases</i> , 2018, 71, 402-407.	0.5	6
279	Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to <i>Neisseria meningitidis</i> serogroup C/cc11, Tuscany, Italy. <i>Vaccine</i> , 2018, 36, 4222-4227.	1.7	22
280	Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine. <i>PLoS ONE</i> , 2018, 13, e0191261.	1.1	15
281	Risk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriage. <i>Infectious Diseases</i> , 2019, 51, 714-717.	1.4	2
282	Carriage prevalence of <i>Neisseria meningitidis</i> in the Americas in the 21st century: a systematic review. <i>Brazilian Journal of Infectious Diseases</i> , 2019, 23, 254-267.	0.3	5
283	<i>S. aureus</i> colonization in healthy Australian adults receiving an investigational <i>S. aureus</i> 3-antigen vaccine. <i>Journal of Infection</i> , 2019, 79, 582-592.	1.7	3
284	Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe. <i>Journal of Infection</i> , 2019, 79, 528-541.	1.7	29
285	The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment. <i>Frontiers in Immunology</i> , 2019, 9, 3151.	2.2	4
287	Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017). <i>BMC Infectious Diseases</i> , 2019, 19, 522.	1.3	34
288	Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. <i>Cell Reports</i> , 2019, 27, 3241-3253.e4.	2.9	26
289	cgMLST characterisation of invasive <i>Neisseria meningitidis</i> serogroup C and W strains associated with increasing disease incidence in the Republic of Ireland. <i>PLoS ONE</i> , 2019, 14, e0216771.	1.1	7
290	B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of <i>Neisseria meningitidis</i> . <i>BMJ Open</i> , 2019, 9, e027233.	0.8	8
291	Protocol for a controlled human infection with genetically modified <i>Neisseria lactamica</i> expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine. <i>BMJ Open</i> , 2019, 9, e026544.	0.8	6
292	Carriage meningococcal isolates with capsule null locus dominate among high school students in a non-endemic period, Italy, 2012-2013. <i>International Journal of Medical Microbiology</i> , 2019, 309, 182-188.	1.5	7
293	Introduction of a second MenB vaccine into Europe - needs and opportunities for public health. <i>Expert Review of Vaccines</i> , 2019, 18, 225-239.	2.0	13
294	Observational study of nasopharyngeal carriage of <i>Neisseria meningitidis</i> in applicants to a military academy in the Russian Federation. <i>International Journal of Infectious Diseases</i> , 2019, 81, 12-16.	1.5	4
295	Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data on laboratory-confirmed cases from 1996 to 2016. <i>Epidemiology and Infection</i> , 2019, 147, e142.	1.0	11
296	An Overview of <i>Neisseria meningitidis</i> . <i>Methods in Molecular Biology</i> , 2019, 1969, 1-16.	0.4	17

#	ARTICLE	IF	CITATIONS
297	Practical Use of Meningococcal Vaccines—Whom and When to Vaccinate. , 2019, , 105-129.		1
298	Meningococcal Vaccine for Hajj Pilgrims: Compliance, Predictors, and Barriers. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 127.	0.9	10
299	A mixed-methods study to identify factors associated with MenACWY vaccine uptake, barriers and motivations towards vaccination among undergraduate students. <i>Health Education Journal</i> , 2019, 78, 189-202.	0.6	7
300	Models of immune selection for multi-locus antigenic diversity of pathogens. <i>Nature Reviews Immunology</i> , 2019, 19, 55-62.	10.6	23
301	Narrative review of methods and findings of recent studies on the carriage of meningococci and other <i>Neisseria</i> species in the African Meningitis Belt. <i>Tropical Medicine and International Health</i> , 2019, 24, 143-154.	1.0	8
302	The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. <i>Expert Review of Vaccines</i> , 2019, 18, 15-30.	2.0	136
303	Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 459-469.	1.4	30
304	Proof of Concept for Prevention of Natural Colonization by Oral Needle-Free Administration of a Microparticle Vaccine. <i>Frontiers in Immunology</i> , 2020, 11, 595320.	2.2	8
305	MenACWY vaccination campaign for adolescents in the Netherlands: Uptake and its determinants. <i>Vaccine</i> , 2020, 38, 5516-5524.	1.7	10
306	Long-term impacts of MenC vaccination campaign in the Salvador, Brazil metropolitan region: A comparison of pre- and post-vaccine periods. <i>Vaccine</i> , 2020, 38, 6267-6273.	1.7	1
307	Broad vaccine protection against <i>Neisseria meningitidis</i> using factor H binding protein. <i>Vaccine</i> , 2020, 38, 7716-7727.	1.7	11
308	Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States. <i>JAMA Pediatrics</i> , 2020, 174, 843.	3.3	26
309	Be on the TEAM™ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. <i>BMJ Open</i> , 2020, 10, e037358.	0.8	11
310	Impact of a Meningococcal Protein-based Serogroup B Vaccine on Serogroup W Invasive Disease in Children. <i>Clinical Infectious Diseases</i> , 2020, 73, e1669-e1672.	2.9	2
311	Rapid Transmission of a Hyper-Virulent Meningococcal Clone Due to High Effective Contact Numbers and Super Spreaders. <i>Frontiers in Genetics</i> , 2020, 11, 579411.	1.1	3
312	Herd Protection against Meningococcal Disease through Vaccination. <i>Microorganisms</i> , 2020, 8, 1675.	1.6	19
313	Impact of Vaccines; Health, Economic and Social Perspectives. <i>Frontiers in Microbiology</i> , 2020, 11, 1526.	1.5	282
314	Meningococcal and pneumococcal carriage in Hajj pilgrims: findings of a randomized controlled trial. <i>Journal of Travel Medicine</i> , 2020, 27, .	1.4	3

#	ARTICLE	IF	CITATIONS
315	Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits. <i>Frontiers in Public Health</i> , 2020, 8, 261.	1.3	8
316	Good News and Bad News – 4CMenB Vaccine for Group B <i>Neisseria meningitidis</i> . <i>New England Journal of Medicine</i> , 2020, 382, 376-378.	13.9	8
317	Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia. <i>New England Journal of Medicine</i> , 2020, 382, 318-327.	13.9	133
318	Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants. <i>Expert Review of Vaccines</i> , 2020, 19, 313-325.	2.0	4
319	Carriage of <i>Neisseria Meningitidis</i> in Low and Middle Income Countries of the Americas and Asia: A Review of the Literature. <i>Infectious Diseases and Therapy</i> , 2020, 9, 209-240.	1.8	13
320	A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global Control. <i>Microorganisms</i> , 2021, 9, 519.	1.6	20
321	Deconvolution of intergenic polymorphisms determining high expression of Factor H binding protein in meningococcus and their association with invasive disease. <i>PLoS Pathogens</i> , 2021, 17, e1009461.	2.1	4
322	Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme. <i>PLoS ONE</i> , 2021, 16, e0250103.	1.1	2
323	Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1 – 4 cross-sectional survey results. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 677-687.	4.6	24
324	Risk factors for carriage of meningococcus in third-level students in Ireland: an unsupervised machine learning approach. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3702-3709.	1.4	3
326	Exploring the Ability of Meningococcal Vaccines to Elicit Mucosal Immunity: Insights from Humans and Mice. <i>Pathogens</i> , 2021, 10, 906.	1.2	2
327	Recent increased incidence of invasive serogroup W meningococcal disease: A retrospective observational study. <i>International Journal of Infectious Diseases</i> , 2021, 108, 582-587.	1.5	3
328	Meningococcal Vaccines of New Generations – the First 20 Years of Use. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2021, 20, 103-113.	0.2	0
329	A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine. <i>Infectious Diseases and Therapy</i> , 2022, 11, 639-655.	1.8	3
330	Factor H binding protein (fHbp)-mediated differential complement resistance of a serogroup C <i>Neisseria meningitidis</i> isolate from cerebrospinal fluid of a patient with invasive meningococcal disease. <i>Access Microbiology</i> , 2021, 3, 000255.	0.2	1
331	Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations. <i>Pathogens and Global Health</i> , 2022, 116, 85-98.	1.0	16
332	Acute Meningitis. , 2010, , 1189-1229.		12
333	Acute Meningitis. , 2015, , 1097-1137.e8.		16

#	ARTICLE	IF	CITATIONS
334	Persistence of Antibody Response Following a Booster Dose of Hib-MenC-TT Glycoconjugate Vaccine to Five Years. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1069-1073.	1.1	12
335	Variation of the factor H-binding protein of <i>Neisseria meningitidis</i> . <i>Microbiology (United Kingdom)</i> , 2009, 155, 4155-4169.	0.7	79
336	Meningococcal C booster not recommended by evidence. <i>BMJ: British Medical Journal</i> , 2008, 337, a1139-a1139.	2.4	8
337	A world without bacterial meningitis: how genomic epidemiology can inform vaccination strategy. <i>F1000Research</i> , 2018, 7, 401.	0.8	13
338	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. <i>Wellcome Open Research</i> , 2019, 4, 118.	0.9	4
339	Influence of Two Vaccination Campaigns on Genetic Diversity of Invasive <i>Neisseria meningitidis</i> Isolates in Northern Spain (1997-2008). <i>PLoS ONE</i> , 2009, 4, e8501.	1.1	8
340	Identifying Optimal Vaccination Strategies for Serogroup A <i>Neisseria meningitidis</i> Conjugate Vaccine in the African Meningitis Belt. <i>PLoS ONE</i> , 2013, 8, e63605.	1.1	36
341	Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands. <i>PLoS ONE</i> , 2013, 8, e65036.	1.1	27
342	Timing of an Adolescent Booster after Single Primary Meningococcal Serogroup C Conjugate Immunization at Young Age; An Intervention Study among Dutch Teenagers. <i>PLoS ONE</i> , 2014, 9, e100651.	1.1	21
343	Effectiveness of Meningococcal C Conjugate Vaccine in Salvador, Brazil: A Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0123734.	1.1	15
344	Optimization of Molecular Approaches to Genogroup <i>Neisseria meningitidis</i> Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines. <i>PLoS ONE</i> , 2015, 10, e0132140.	1.1	18
345	Meningococcal Carriage in Military Recruits and University Students during the Pre MenB Vaccination Era in Greece (2014-2015). <i>PLoS ONE</i> , 2016, 11, e0167404.	1.1	14
346	Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. <i>MMWR Recommendations and Reports</i> , 2020, 69, 1-41.	26.7	175
347	Prevention of Meningococcal Infections in the First 2 Years of Life. <i>Pediatric Annals</i> , 2013, 42, 164-71.	0.3	5
348	Intracluster correlation coefficients in a large cluster randomized vaccine trial in schools: Transmission and impact of shared characteristics. <i>PLoS ONE</i> , 2021, 16, e0254330.	1.1	0
349	Meningococcal disease and vaccination in college students. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4675-4688.	1.4	4
351	The Impact of Horizontal Genetic Exchange on Bacterial Population Structure: Insights from the Genera <i>Neisseria</i> and <i>Campylobacter</i> . , 0, , 15-30.		0
353	Evolution of Different Bacterial Meningoencephalitis: Series of Case Presentations and Literature Review. <i>ARS Medica Tomitana</i> , 2019, 25, 142-148.	0.0	0

#	ARTICLE	IF	CITATIONS
354	OUP accepted manuscript. American Journal of Epidemiology, 2021, , .	1.6	1
355	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. Wellcome Open Research, 2019, 4, 118.	0.9	2
356	4CMenB vaccine and its role in preventing transmission and inducing herd immunity. Expert Review of Vaccines, 2022, 21, 103-114.	2.0	7
357	Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics. Transactions of the American Clinical and Climatological Association, 2011, 122, 115-23.	0.9	28
358	Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage. Journal of Preventive Medicine and Hygiene, 2015, 56, E116-20.	0.9	39
359	Meningococcal B vaccination strategies and their practical application in Italy. Journal of Preventive Medicine and Hygiene, 2015, 56, E133-9.	0.9	9
362	Detection of Neisseria meningitidis in saliva and oropharyngeal samples from college students. Scientific Reports, 2021, 11, 23138.	1.6	9
363	Neisseria lactamica Controlled Human Infection Model. Methods in Molecular Biology, 2022, 2414, 387-404.	0.4	3
364	Control of serogroup W meningococcal disease outbreaks: the promise of adolescent vaccination. The Lancet Child and Adolescent Health, 2022, 6, 73-75.	2.7	0
365	Meningococcal Disease in Pediatric Age: A Focus on Epidemiology and Prevention. International Journal of Environmental Research and Public Health, 2022, 19, 4035.	1.2	5
366	Epidemiology and economic burden of meningococcal disease in Germany: A systematic review. Vaccine, 2022, 40, 1932-1947.	1.7	4
367	Hospitalizations related to meningococcal infection in Spain from 1997 to 2018. BMC Infectious Diseases, 2021, 21, 1215.	1.3	1
371	Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage. Expert Review of Vaccines, 2022, 21, 753-769.	2.0	2
373	Preventing invasive meningococcal disease in early infancy. Human Vaccines and Immunotherapeutics, 2022, 18, 1-11.	1.4	2
374	Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy. Vaccines, 2022, 10, 778.	2.1	0
375	Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clinical Microbiology and Infection, 2022, 28, 1649.e1-1649.e8.	2.8	20
376	Impact of COVID-19 Containment Strategies and Meningococcal Conjugate ACWY Vaccination on Meningococcal Carriage in Adolescents. Pediatric Infectious Disease Journal, 2022, 41, e468-e474.	1.1	3
377	Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	6

#	ARTICLE	IF	CITATIONS
378	Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa. <i>Vaccine</i> , 2022, 40, 6042-6047.	1.7	1
380	Historical review of vaccination against meningococcus in Spain (1996–2021). Learned lessons. <i>Vacunas (English Edition)</i> , 2023, 24, 45-54.	0.3	1
386	Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines. , 2023, , 664-689.e12.		0
387	Meningococcal Vaccines Directed at Capsular Group B. , 2023, , 690-710.e7.		0
388	Community Protection. , 2023, , 1603-1624.e8.		0
389	Bacterial Meningitis. , 2024, , 405-414.		0